Statins in Breast Cancer Therapy: Mechanistic Insights and Emerging Evidence
Cancer Innovation, Volume 5, Issue 1, February 2026.Statins, particularly simvastatin, demonstrate potential as adjuvant agents in breast cancer treatment by disrupting tumour cell signalling and survival pathways. This review highlights emerging evidence supporting their repurposing for improved outcomes, especially in aggressive breast cancer subtypes.
Rohina Alim, H. M. Kasuni Akalanka
wiley +1 more source
Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature. [PDF]
Front OncolLendinez-Sanchez G +6 more
europepmc +1 more source
Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer
Cancer Innovation, Volume 5, Issue 1, February 2026.Potential biomarkers for the development of targeted radionuclide therapy that can be employed in the treatment of breast cancer have been summarised in the review. They include receptor markers of ER, PR and HER2, as well as other markers of Trop2, PD‐1, EGFR, GRPR and PSMA.
Yujing Tan +3 more
wiley +1 more source
Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification. [PDF]
JAAD Case RepNassief G, Butt OH, Zhou AY, Ansstas G.
europepmc +1 more source
Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials. [PDF]
J Mark Access Health Policy, 2022 Fan L +7 more
europepmc +1 more source
A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series
Cancer Medicine, Volume 15, Issue 2, February 2026.ABSTRACT Hepatoid adenocarcinoma (HAC) is a rare extrahepatic tumor of non‐germ cell origin that morphologically resembles hepatocellular carcinoma (HCC). HAC has a propensity to metastasize to the liver and therefore may be mistaken for HCC. There is a lack of standardized treatment protocols, and further studies are needed to evaluate the benefit of ...
Christina Liava +4 more
wiley +1 more source
The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma. [PDF]
Front Oncol, 2021 Pletcher JP +6 more
europepmc +1 more source
DNTTIP1 drives leukaemogenesis through MiDAC‐mediated epigenetic silencing of BMF
Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.DNTTIP1 cooperates with SP1 to recruit HDAC1/2, leading to BMF silencing and reduced competitive binding of BMF to BCL2.This suppresses autophagy and apoptosis, promoting leukaemic cell survival. Targeting the DNTTIP1‐HDAC1/2‐BMF axis reactivates BMF and induces anti‐leukaemic effects.
Ruolin Xiu +12 more
wiley +1 more source
Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy. [PDF]
OncotargetValdez BC +7 more
europepmc +1 more source
Salvia coccinea and Apigenin: A Natural Treasure of Lamiaceae in Pharmacological Innovation
Food Science &Nutrition, Volume 14, Issue 2, February 2026.Salvia coccinea is rich in bioactive phytochemicals, notably the flavonoid apigenin, offering strong antioxidant, anti‐inflammatory, and antimicrobial effects. By modulating inflammatory and oxidative pathways, it shows potential for managing chronic diseases.
Muhammad Usman Khalid +7 more
wiley +1 more source